Yayınlar

1. Haznedaroğlu IC, Üstündağ Y, Benekli M, Savaş MC, Safalı M, Dündar SV. Isolated gingival relapse during complete hematological remission in acute promyelocytic leukemia. Acta Haematologica 1995;93:54-55.

2. Benekli M, Savaş MC, Haznedaroğlu İC, Dündar SV. Two cases of extramedullary acute promyelocytic leukemia. Cancer 1995;76:151-152.

3. Benekli M, Savaş MC, Güllü İH, Kadayıfçı A, Akpek G, Kars A, Güler N, Kansu E, Tekuzman G, Fırat D. Tumor lysis syndrome following single-dose mitoxantrone. Chemotherapy 1995;41:470-472.

4. Haznedaroğlu İC, Benekli M, Dündar S. Thrombopoietin, megakaryocytopoietic cytokines and reactive versus clonal megakaryocytopoesis: An enigma complex. Blood 1996;87:1654.

5.  Kiraz S, Ertenli İ, Benekli M, Çalgüneri M. Parvovirus B19 infection in Behçet’s disease. Clinical and Experimental Rheumatology 1996;14:71-73.

6.  Güllü İH, Benekli M, Müderrisoğlu H, Oto A, Kansu E, Kabakçı G, Oram E, Bekdik C. Silent myocardial ischemia in Behçet’s disease. Journal of Rheumatology 1996;23:323-327.

7.  Kadayıfçı A, Savaş MC, Benekli M. Risks and benefits in bleeding patients on oral anticoagulation. Lancet 1996;348:1108.

8.  Benekli M, Güllü İH, Savaş MC, Kadayıfçı A, Altundağ MK, Tekuzman G, Fırat D. Acute tumor lysis syndrome following intrathecal methotrexate. Leukemia&Lymphoma 1996;22:361-363.

9.  Benekli M, Savaş MC, Haznedaroğlu İC, Dündar SV. Granulocytic sarcoma in acute promyelocytic leukemia. Leukemia&Lymphoma 1996;22:183-186.

10.  Kadayıfçı A, Benekli M, Şimşek H, Şencan O. Prostatic acid phosphatase and prostate specific antigen in liver disease. International Urology and Nephrology 1996;28:67-71.

11.  Benekli M, Büyükaşık Y, Haznedaroğlu İC, Savaş MC, Özcebe Oİ. Chronic lymphocytic leukemia presenting as acute urinary retention due to leukemic infiltration of prostate. Annals of Hematology 1996;73:143-144.

12.  Kiraz S, Şimşek H, Ertenli İ, Benekli M, Kadayıfçı A, Çalgüneri M. Antineutrophil cytoplasmic antibodies in systemic sclerosis. Clinical Rheumatology 1996;15:519-20.

13.  Kiraz S, Baltalı E, Güler N, Barışta İ, Benekli M, Çelik İ, Güllü İH, Kars A, Tekuzman G, Fırat D. Ifosfamide, mesna and epirubicin as second-line chemotherapy in advanced breast cancer. Journal of Chemotherapy 1996;8:310-314.

14.  Haznedaroğlu İC, Savaş MC, Benekli M, Güllü İH, Dündar SV. The significance of megakaryocytopoietic cytokines and thrombopoietin in immune thrombocytopenic purpura: A hypothesis. New Zealand Medical Journal 1996;109:389.

15.  Çalgüneri M, Kiraz S, Ertenli İ, Benekli M, Karaarslan Y, Çelik İ. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet’s disease. Arthritis and Rheumatism 1996;39:2062-2065.

16.  Savaş MC, Benekli M, Haznedaroğlu İC, Dündar SV. Bulky plasmacytoma of the skull with intracranial involvement. American Journal of Hematology 1997;54:173.

17.  Savaş MC, Benekli M, Akçay A, Birdane A. Heparin-associated refractory bronchospasm. Annals of Pharmacotherapy 1997;31:253.

18.  Benekli M, Kars A, Güler N. Mitoxantrone-induced bradycardia. Annals of Internal Medicine 1997;126:409.

19.  Benekli M, Savaş MC, Haznedaroğlu İC. Extramedullary acute promyelocytic leukemia. Cancer 1997;80:518-519.

20.  Haznedaroğlu İC, Savaş MC, Benekli M, Sayınalp NM, Özcebe Oİ, Dündar S. Acute lymphoblastic leukemia occurring in a case of chronic lymphocytic leukemia. Hematology 1997;2:87-89.

21.  Şahin S, Hindioğlu U, Benekli M, Sivri B, Sökmensüer C, Sungur A. Peculiar inflammatory cutaneous metastasis from stomach adenocarcinoma. British Journal of Dermatology 1997;136:650-652.

22.  Kadayıfçı A, Benekli M, Savaş MC, Aslan S, Uzunalimoğlu B, Barışta İ, Güllü İH, Tekuzman G. Multiple lymphomatous polyposis. Journal of Surgical Oncology 1997;64:336-340.

23.  Kadayıfçı A, Arslan S, Benekli M, Sökmensüer C. Periampullary carcinoma in a patient with sarcoidosis. Sarcoidosis 1997;14:87-8.

24.  Kiraz S, Baltalı E, Güler N, Barışta İ, Benekli M, Çelik İ, Güllü İH, Kars A, Tekuzman G, Fırat D. Ifosfamide and etoposide in previously treated patients with advanced breast cancer. Tumori 1997;83:604-607.

25.  Savaş MC, Çelik İ, Benekli M, Kars A. Hyalinising trabecular adenoma of thyroid masquerading as thyroid carcinoma. Acta Oncologica 1997;36:436-437.

26.  Öztürk MA, Benekli M, Güler N, Altundağ MK, Barışta İ, Ayhan A. Gastric adenocarcinoma metastasis to the parotid gland. Journal of Clinical Gastroenterology 1997; 25: 698-9.

27.  Benekli M, Akpek G, Güllü İH, Ruacan Ş, Barışta İ, Ayhan A, Tekuzman G, Fırat D. Small intestinal perforation in a patient with Hodgkin’s disease. Journal of Clinical Gastroenterology 1997;25:699-701.

28.  Haznedaroğlu İC, Savaş MC, Benekli M. Renin-like activity in leukemic blast cells: An initial clue for a local renin-angiotensin system in the bone marrow. Annals of Hematology 1997;75:69-70.

29.  Çalgüneri M, Kiraz S, Ertenli İ, Benekli M, Karaarslan Y, Çelik İ. Reply: letter to the editor. Arthritis and Rheumatism 1997;40:1728-1730.

30.  Benekli M, Güllü İH. Hippocratic fingers in Behçet’s disease. Postgraduate Medical Journal 1997;73:575-576.

31.  Haznedaroğlu İC, Büyükaşık Y, Benekli M, Güllü İH. Real-Working classification of lymphoid neoplasms: The golden prefix. Journal of National Cancer Institute 1997;89:1546.

32.  Benekli M, Yalçın B, Güler N, Tekuzman G. Disseminated morphea in small cell lung cancer. Acta Dermato-Venereologica 1998;78:72-73.

33.  Benekli M, Savaş MC, Erdem Y, Yalçın AU, Yasavul Ü, Turgan Ç, Çağlar Ş. Primary hyperparathyroidism in a patient with systemic lupus erythematosus-antiphospholipid syndrome. Nephron 1998;79:215-216.

34.  Savaş MC, Çelik İ, Benekli M, Güllü İH, Tekuzman G. Renal cell carcinoma presenting as a solitary cervical node metastasis compressing brachial plexus. Nephron 1998;79:107-108.

35.  Öztürk MA, Benekli M, Altundağ MK, Güler N. Squamous cell carcinoma in a patient with systemic sclerosis. Dermatologic Surgery 1998;24:777-779.

36.  Benekli M, Güllü İH, Tekuzman G, Savaş MC, Hayran M, Hasçelik G, Fırat D. Circulating intercellular adhesion molecule-1 and E-selectin in gastric cancer. British Journal of Cancer 1998;78:267-271.

37.  Benekli M, Güllü İH, Haznedaroğlu İC. Ischemic heart disease in Behçet’s syndrome. Rheumatology International 1998;17:251.

38.  Benekli M, Haznedaroğlu İC, Erdem Y. Glomerular disease in Behçet’s disease (Invited Editorial Comment). Nephrology Dialysis Transplantation 1998;13:1351-1354.

39.  Barışta İ, Benekli M, Tekuzman G. Amyloidosis in Hodgkin’s and Castleman’s diseases. Annals of Oncology 1999;10:998-999.

40.  Kiraz S, Ertenli İ, Benekli M, Haznedaroğlu İC, Çalgüneri M, Çelik İ, Apraş Ş, Kirazlı Ş. Clinical significance of hemostatic markers and thrombomodulin in systemic lupus erythematosus: Evidence for a prothrombotic state. Lupus 1999;8:737-741.

41.  Haznedaroğlu İC, Benekli M, Ozcebe O, Savaş MC, Güllü İH, Dündar SV, Kirazlı Ş. Serum L-selectin and P-selectin levels in lymphomas. Haematologia 2000;30:27-30.

42.  Benekli M, Anderson B, Wentling D, Bernstein S, Czuczman M, McCarthy PL. Severe respiratory depression after dimethylsulphoxide-containing autologous stem cell infusion in a patient with AL amyloidosis. Bone Marrow Transplantation 2000;25:1299-1301.

43.  Benekli M, Xia Z, Donohue KA, Ford LA, Pixley LA, Baer MR, Baumann H, Wetzler M. Constitutive activity of signal transducer and activator of transcription (STAT) 3 protein in acute myeloid leukemia (AML) blasts is associated with short disease-free survival. Blood 2002;99:252-57.

44.  Haznedaroglu IC, Goker H, Turgut M, Buyukasik Y, Benekli M. Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions. Clinical and Applied Thrombosis Haemostasis 2002;8:193-212.

45.  Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activatorof transcription proteins in leukemias. Blood 2003;101:2940-2954.

46.  Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR. Drug interaction between simvastatin and fluconazole causing rhabdomyolysis. Annals of Pharmacotherapy 2003;37:1032-1035.

47.  Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS, Bernstein ZP, Chanan-Khan AA, Becker JL, McCarthy PL Jr. The effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin lymphoma patients. Bone Marrow Transplantation 2002;32:139-143.

48.  Benekli M, Crane JK, Conti RR, Kremzier JE, Bidani R. Pulmonary mucormycosis in a patient with chronic obstructive pulmonary disease: diagnosis by fine needle aspiration cytology. Journal of Thoracic and Cardiovascular Surgery 2004;127:588-9.

49.  Benekli M, Hahn T, Wong C, Moysich KB, Hyland A, Michalek AM, Alam A, Baer MR, Bambach B, Czuczman MS, Wetzler M, Becker JL, McCarthy, Jr PL. A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin’s disease.  Bone Marrow Transplantation 2005;35:557-66.

50. Oktar SO, Yucel C, Demiroğullari T, Uner A, Benekli M, Erbas G, Ozdemir H.  Doppler sonographic evaluation of hemodynamic changes in colorectal liver metastases relative to liver size. Journal of Ultrasound Medicine 2006;25:575-82.

51.  Benekli M, Hahn T, Williams BT, Cooper M, Roy HN, Wallace P, Stewart C, Bambach B, McCarthy, Jr PL. Muromonab-CD3 (Orthoclone OKT3^®), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.  Bone Marrow Transplantation 2006;38:365-370.

52. Yolcu OF, Koklu S, Yuksel O, Coban S, Ayaz S, Ozturk MA, Benekli M. Vascular endothelial growth factor receptor-1 levels in hepatocellular carcinoma and correlations with clinicopathological features. Hepatogastroenterology 2007;54:1526-1528

53.  Yaman E, Uner A, Er O, Coskun U, Buyukberber S, Dikilitas M, Polat M, Yamac D, Kaya AO, Yildiz R, Ozturk B, Benekli M. Capecitabine plus oxaliplatin (XELOX) in the treatment of chemotherapy-naïve patients with metastatic colorectal cancer. Medical Oncology 2007;24:431-435.

54.  Benekli M, Yildiz R, Uner A, Er O, Yamac D, Alkis N, Coskun U, Camci C, Buyukberber S. Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Oncology (Basel) 2007;72:308-13.

55.  Coskun U, Buyukberber S, Yaman E, Er O, Uner A, Ozkan M, Dikilitas M, Oguz M, Yildiz R, Benekli M. XELOX (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients. Neoplasma 2008;55:65-70.

56.  Yildiz R, Coskun U, Kapucu O, Kaya AO, Akdemir UO, Benekli M, Buyukberber S. F-18 FDG uptake due to Acinetobacter infection causing misinterpretation of treatment response in a lymphoma patient. Clinical Nuclear Medicine2007;32:471-473.

57.  Yaman E, Coskun U, Buyukberber S, Ozturk B, Kaya AO, Yildiz R, Uner A, Yamac D, Benekli M. Persistent elevation of CA 19-9 in an apparently healthy 56-year-old woman. LabMedicine 2007;38: 485-486.

58.  Ozturk B, Buyukberber S, Coskun U, Yaman E, Yildiz R, Kaya AO, Oner Y, Benekli M. Solitary iris metastasis from breast cancer with dramatic course: case report. Medical Oncology. 2007;24:463-465.

59.  Uner A, Ozturk B, Benekli M, Coskun U, Kocak S, Kaya AO, Unsal D, Erekul S, Yaman E, Yildiz R, Buyukberber S. Synchronized primary breast osteosarcoma and contralateral benign cystosarcoma phyllodes: Radiological and pathological imaging. Breast Journal 2008;14:109-110.

60.  Yaman E, Benekli M, Coskun U, Ozturk B, Kaya AO, Yildiz R, Buyukberber S. Reply to the article "Oral ibandronate is as active as i.v. zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases" by J.-J. Body et al. Annals of Oncology 2008;19:397-398

61.  Benekli M, Smiley S, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, Padmanabhan S, McCarthy, PL Jr, Hahn T. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.  Bone Marrow Transplantation2008;41:613-619.

62.  Ozturk B, Buyukberber S, Akmansu M, Coskun U, Yamac D, Uner A, Yaman E, Yildiz R, Kaya AO, Bora H, Unsal D, Pak Y, Benekli M. The results of three different treatment modalities in patients with locally advanced nasopharyngeal carcinoma. Medical Oncology 2008;25:269-273.

63.  Coskun U, Kaya AO, Buyukberber S, Benekli M, Uner A, Dikilitas M, Ozturk B, Yildiz R, Ozkan S, Yaman E, Yamac D. Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens. Medical Oncology 2008;25:133-136.

64.  Berk V, Yildiz R, Akdemir UO, Akyurek N, Karabacak NI, Coskun U, Benekli M. Disseminated extranodal NK/T-cell lymphoma, nasal type, with multiple subcutaneous nodules: Utility of 18F-FDG PET in staging. Clinical Nuclear Medicine 2008;33:365-366.

65.  Yaman E, Buyukberber S, Uner A, Coskun U, Akmansu M, Uncu D, Zengin N, Benekli M, Yamac D, Ozturk B, Kaya AO, Yildiz R, Ozkan S, Gunel N. Temozolomide in newly diagnosed malignant gliomas administered concomitantly with radiotherapy and thereafter as consolidation treatment. Onkologie 2008;31:309-313.

66.  Yaman E, Buyukberber S, Uner A, Coskun U, Yamac D, Ozturk B, Kaya AO, Yildiz R, Benekli M. Carboplatin and oral cyclophosphamide combination after temozolomide failure in malignant gliomas. Tumori 2008;94:674-680.

67.  Coskun U, Buyukberber S, Yaman E, Er O, Uner A, Ozkan M, Dikilitas M, Oguz M, Yildiz R, Benekli M. XELOX (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients. Neoplasma 2008;55:65-70.

68.  Kaya AO, Coskun U, Unlu M, Akdemir UO, Ozdemir NY, Zengin N, Benekli M, Yildiz R, Yaman E, Ozturk B, Gumus M, Uner A, Yamac D, Ucgul E, Buyukberber S. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with metastatic carcinoma of unknown origin. Asian Pacific Journal of Cancer Prevention 2008;9:683-686.

69.  Bostankolu Ö, Öztürk B, Coşkun U, Buyukberber S, Benekli M. Cancer chemotherapy in elderly patients. International Journal of Hematology and Oncology 2008;18:186-192.

70.  Kaya AO, Yıldız R, Öztürk B, Yaman E, Barıt G, Coşkun U, Üner A, Benekli M, Yamaç D, Büyükberber S. Synchronous squamous cell lung carcinoma and rectum adenocarcinoma: case report. International Journal of Hematology and Oncology 2008;18:42-45.

71. Yaman E, Benekli M, Coskun U, Sezer K, Ozturk B, Kaya AO, Yildiz R, Uluoglu O, Buyukberber S. Intrasellar plasmacytoma: an unusual presentation of multiple myeloma. Acta Neurochirurgica (Wien) 2008;150:921-924.

72.  Kaya AO, Buyukberber S, Coskun U, Yildiz R, Ozturk B, Yaman E, Adisen E, Gureli M, Benekli M. Acute erythema and edematous skin reaction and ectropion following docetaxel in a patient with non-small cell lung cancer. Cutaneous and Ocular Toxicology 2008;27:327-331.

73.  Yaman E, Ozturk B, Erdem O, Gokcora N, Coskun U, Uluoglu O, Benekli M. Histiocytic sarcoma: PET-CT evaluation of a rare entitiy. Annals of Nuclear Medicine 2008;22:715-717.

74.  Yaman E, Coskun U, Benekli M, Sozen S, Yamac D, Buyukberber S, Ozturk B, Kaya AO, Yildiz R, Tezel E. Coexistence of gastrointestinal stromal tumor of rectum and adenocarcinoma of prostate in a patient with family history of gastrointestinal stromal tumor. Onkologie 2008;31:697-699.

75.  Ozturk B, Tacoy G, Coskun U, Yaman E, Sahin G, Buyukberber S, Yildiz R, Kaya AO, Topal S, Ozdemir M, Benekli M. Gemcitabine-induced acute coronary syndrome: a case report. Medical Principles and Practice 2009;18:76-80.

76.  Yaman E, Coskun U, Ozturk B, Buyukberber S, Kaya AO, Coskun O, Buyukberber N, Yildiz R, Benekli M. Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma. Journal of Clinical Neuroscience 2009;16:591-592.

77.  Ozturk B, Coskun U, Sancak B, Yaman E, Buyukberber S, Benekli M. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. International Immunopharmacology 2009;9:645-648.

78.  Yildiz R, Benekli M, Akyurek N,  Coskun U, Kaya AO,  Ozturk B,  Yaman E, Buyukberber S. Non-gestational uterine choriocarcinoma in a postmenopausal woman: a case report. Onkologie 2009;32:417-419.

79.  Karaoglu A, Arslan UY, Ozkan M, Kalender ME, Alici S, Coskun U, Gumus M, Celenkoglu G, Er O, Sevinc A, Buyukberber S, Alkis N, Benekli M. Efficacy and toxicity of gemcitabine and pgylated liposomal doxorubicin in recurrent platinum-resistant/refractory epithelial ovarian cancer. Asian Pacific Journal of Cancer Prevention 2009;10:63-66.

80.  Ozturk B, Coskun U, Yaman E, Kaya AO, Yildiz R, Benekli M, Buyukberber S. The risk factors, premalignant lesions and chemoprevention oral cavity cancers. International Journal of Hematology and Oncology 2009;19:117-126.

81.  Kaya AO, Coskun U, Sancak B, Buyukberber S, Yildiz R, Gulbahar O, Benekli M, Ozenirler S. Increased serum granulocyte colony stimulating factor in Turkish hepatocellular carcinoma patients. Asian Pacific Journal of Cancer Prevention 2009;10:403-405.

82.  Benekli M, Baumann H, Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. Journal of Clinical Oncology 2009;27:4422-4432.

83.  Ozturk B, Coskun U, Yaman E, Cakir A, Akdemir UO, Yildiz R, Akyol G, Demirci U, Buyukberber S, Tezel E, Benekli M. Adult hepatic epitheloid haemangioendothelioma presenting with Kasabach-Merrit syndrome: a case report. Journal of Clinical Pathology 2009;62(11): 1053-1055.

84.  Coskun U, Alkis N, Celenkoglu G, Buyukberber S, Ozkan M, Camci C, Uner A,  Er O, Aslan UY, Sevinc A, Tokluoglu S, Ozturk B, Yildiz R, Benekli M.  Gemcitabine combined with uracil-tegafur (UFT) in patients with advanced pancreatic cancer. Journal of National Medical Association 2009;101:761-764.

85.  Demirci U, Coskun U, Sancak B, Ozturk B, Bahar B, Benekli M, Buyukberber S. Serum granulocyte macrophage-colony stimulating factor: a tumor marker in colorectal carcinoma? Asian Pacific Journal of Cancer Prevention 2009;10:1021-1024.

86.  Alici S, Coskun U, Alkis N, Sevinc A, Dane F, Gumus M, Ozkan M, Kaya AO, Celenkoglu G, Buyukberber S, Altinbas M, Benekli M. Vinorelbine in combination with carboplatin followed by single-agent consolidation therapy for unresectable localized or metastatic non-small-cell lung carcinomas. Asian Pacific Journal of Cancer Prevention 2009;10;1051-1055.

87.  Coskun U, Kaya AO, Alkis N, Buyukberber S, Alici S, Celenkoglu G, Uncu D, Ozkan M, Sevinc A, Benekli M.  UFT plus oral folinic acid alternating oral and intravenous vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxanes. Onkologie 2009;32:562-566.

88.  Kaya AO, Buyukberber S, Benekli M, Coskun U, Sevinc A, Akmansu M, Yildiz R, Ozturk B, Yaman E, Kalender ME, Orhan O, Yamac D, Uner A. Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally-advanced non-small cell lung cancer. Medical Oncology 2010;27:152-157.

89.  Demirci U, Büyükberber S, Yılmaz G, Oztürk B, Akyürek N, Yıldız R, Tonyalı O, Coşkun U, Benekli M. Coexistence Hodgkin's lymphoma and colonic adenocarcinoma: a case report. Medical Oncology 2010;27:62-64.

90.  Baykara M, Coskun U, Demirci U, Yildiz R, Benekli M, Cakir A, Buyukberber S. Intracystic papillary carcinoma of the breast: one of the youngest patient in the literature. Medical Oncology 2010;27:1427-1428.

91.  Yildiz R, Buyukberber S, Uner A, Yamac D, Coskun U, Kaya AO, Ozturk B, Yaman E, Benekli M. Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Cancer Investigation 2010;28:33-37.

92.  Demirci U, Buğdaycı F, Cakır A, Gürlek B, Gönül II, Büyükberber S, Benekli M, Coşkun U. Bilateral breast cancer in a survivor of acute lymphoblastic leukemia: a case report. Medical Oncology2010;27:481-483.

93.  Kaya AO, Büyükberber S, Yamaç D, Coşkun U, Yıldız R, Yaman E, Öztürk B, Benekli M. Changes in hormone receptor and Her2 status after neoadjuvant chemotherapy in breast cancer. Türkiye Klinikleri Journal of Medical Sciences. 2010;30:469-473.

94.  Yaman E, Coskun U, Guner AL, Erdem O, Ozturk B, Buyukberber S, Benekli M, Kitapçı M. Aggressive extraocular sebaceous carcinoma originating from lumbar skin with disseminated lymphadenopathies: A PET-CT evaluation. Türkiye Klinikleri Journal of Medical Sciences 2010;30:1395-1398.

95.  Kaya AO, Coşkun U, Büyükberber S, Benekli M, Tekin E, Cifter C, Öztürk B, Yıldız R, Yaman E, Uner A, Yamaç D.Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer. Journal of BUON 2010;15:248-254.

96.  Yildiz R, Kalender ME, Dane F, Sevinc A, Gumus M, Camci C, Alici S, Kaya AO, Yaman E, Öztürk B, Coskun U, Benekli M, Uncu D, Buyukberber S. Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens. Journal of Oncology Pharmacy Practice 2010;16:173-178.

97.  Tonyali O, Coskun U, Yildiz R, Karakan T, Demirci U, Akyurek N, Benekli M, Buyukberber S. Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Medical Oncology  2010;27:768-773.

98.  Yaman E, Buyukberber S, Benekli M, Oner Y, Coskun U, Akmansu M, Ozturk B,Kaya AO, Uncu D, Yildiz R. Radiation induced early necrosis in patients with malignant gliomas receiving temozolomide. Clinical Neurology and Neurosurgery  2010;112:662-667.

99.  Demirci U, Buyukberber S, Yildiz R, Benekli M, Coskun U. Significance of hormonal treatment in metastatic breast cancer. UHOD 2010;20:186-189.

100.  Yildiz R, Benekli M, Buyukberber S, Kaya AO, Ozturk B, Yaman E, Berk V,Coskun U, Yamac D, Sancak B, Uner A. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.  Journal of Cancer Research and Clinical Oncology 2010;136(10):1471-1476.

101.  Yaman E, Ozturk B, Coskun U, Buyukberber S, Kaya AO, Yildiz R, Benekli M. Synchronous bilateral breast cancer in an aged male patient. Onkologie 2010;33:255-258.

102.  Ustaalioglu BBO, Gumus M, Unal A, Cayir K, Sever O, Bilici A, Elkiran ET, Karaca H, Benekli M, Karaoglu A, Seker M. Malignancies diagnosed during pregnancy and treated with chemotherapy or other modalities (review of 27 cases) multicenter experiences. International Journal of Gynecological Cancer 2010;20:698-703.

103.  Demirci U, Coşkun U, Göçün PU, Gurlek B, Saka B, Oztürk B, Benekli M, Büyükberber S. Four different malignancies in one patient: a case report. Cases Journal 2010;3:53.

104.  Demirci U, Buyukberber S, Cakir A, Ozturk B, Akyurek N, Unver B, Baykara M, Benekli M, Coskun U. Synchronous testicular liposarcoma and prostate adenocarcinoma: a case report. Cases Journal 2010;3:27.

105.  Yaman E, Coskun U, Sancak B, Buyukberber S, Ozturk B, Benekli M. Serum M30 levels are associated with survival in advanced gastric carcinoma patients. International Immunopharmacology 2010;10(7):719-22.

106.  Ozturk B, Coskun U, Yaman E, Akdemir O, Cakir A, Memis L, Sezer K, Kaya AO, Yildiz R, Demirci U, Benekli M, Oguz M, Buyukberber S. A case of extra-adrenal paraganglioma localized in retroperitoneum diagnosed with FDG-PET: case report and review of the literature. Endocrinologist 2010;20:60-62.

107.  Kaya AO, Buyukberber S, Dane F, Isikdogan A, Ustaalioglu BO, Coskun U, YumukPF, Dogu GG, Ozdemir NY, Sevinc A, Gumus M, Ozkan M, Yildiz R, Ozturk B, Yaman E, Benekli M; Anatolian Society of Medical Oncology. Cisplatin plus docetaxel combination in the first-line treatment of metastatic non-small cell lung cancer. Tumori 2010;96(3):400-404.

108.  Bahar B, Cayci B, Coşkun U, Büyükberber S, Benekli M, Yildiz R. Granulocyte colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) as potential tumor markers in non small cell lung cancer diagnosis. Asian Pacific Journal of Cancer Prevention 2010;11(3):709-712.

109.  Demirci U, Benekli M, Buyukberber S, Coskun U. Late side effects of cancer therapy. UHOD 2010;20:250-261.

110.  Cetin B, Buyukberber S, Sentürk S, Güzel E, Coskun U, Benekli M. Ischemic colitis after capecitabine plus cisplatin treatment in advanced gastric cancer. Journal of Thrombosis and Thrombolysis 2011;31(4):503-506.

111.  Seker M, Bilici A, Ustaalioglu BO, Yilmaz B, Ozturk B, Unal A, Dane F,Ozdemir NY, Elkiran ET, Kalender ME, Gumus M, Benekli M. Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast. Archives of  Gynecology and Obstetrics 2011;284(2):405-409.

112.  Cetin B, Coskun U, Yildiz R, Buyukberber S, Baykara M, Benekli M. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus. Journal of Oncology Pharmacy Practice 2011 Sep;17(3):274-8.

113.  Demirci U, Coskun U, Erdem O, Ozturk B, Bilge Yilmaz I, Benekli M, Buyukberber S. Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient. Journal of Oncology Pharmacy Practice 2011;17(3):285-287.

114.  Uner A, Akyurek N, Saglam A, Abdullazade S, Uzum N, Onder S, Barista I,Benekli M. The presence of Epstein-Barr virus (EBV) in diffuse large B-celllymphomas (DLBCLs) in Turkey: special emphasis on 'EBV-positive DLBCL of the elderly'. APMIS 2011 Apr;119(4-5):309-16.

115.  Yildiz R, Coskun U, Buyukberber S, Sancak B, Kaya AO, Gulbahar O, Benekli M. Serum granulocyte colony-stimulating factor levels in gliomas. Journal of BUON 2011;16:138-41.

116.  Alkis N, Demirci U, Benekli M, Yilmaz U, Isikdogan A, Sevinc A, Ozdemir NY, Koca D, Yetisyigit T, Kaplan MA, Uncu D, Unek T, Gumus M. Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure. Journal of BUON 2011;16(1):80-3.

117.  Baykara M, Akkus M, Yildiz R, Gonul II, Dursun A, Coskun U, Benekli M, SevincA, Dane F, Buyukberber S. Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma. International Immunopharmacology 2011;11(12):2227-31.

118.  Tanindi A, Demirci U, Tacoy G, Buyukberber S, Alsancak Y, Coskun U, Yalcin R, Benekli M. Assessment of right ventricular functions during cancer chemotherapy. European Journal of Echocardiography 2011;12(11):834-40.

119.  Cetin B, Benekli M, Bulutay P, Akyurek N, Cura E, Coskun U, Buyukberber S. Sister Mary Joseph's nodule as a rare sign of lymphoma. International Journal of Hematology 2011;94(2):209-212.

120.  Çetin B, Büyükberber S, Yüksel M, Coşkun U, Yildiz R, Benekli M. Metastasis of rectal cancer to soft tissue of the hand: an unusual case. Turkish Journal of Gastroenterology 2011;22(2):229-30.

121.  Cetın B, Büyükberber S, Yilmaz IB, Yildiz R, Coşkun U, Benekli M. Kaposi's sarcoma in patients with ulcerative colitis receiving immunosuppressive drugs: report of a case. Turkish Journal of Gastroenterology 2011;22(6):621-5.

122.  Demirci U, Buyukberber S, Cakir T, Poyraz A, Baykara M, Karakus E, Tufan G, Benekli M, Coskun U. Isolated mucinous adrenal metastasis in a breast cancer patient. Journal of Oncology Pharmacy Practice 2011;17:444-7.

123.  Cetin B, Cetin Z, Buyukberber S, Gonul II, Sahiner I, Coskun U, Benekli M. Generalized lymphadenopathy: unusual presentation of prostate adenocarcinoma. Case Reports in Urology 2011;2011:439732.

124.  Demirci U, Coskun U, Akdemir UO, Benekli M, Kapucu O, Ozkan S, Cakir T, Baykara M, Buyukberber S. The nodal standard uptake value (SUV) as a prognostic factor in head and neck squamous cell cancer. Asian Pacific Journal of Cancer Prevention 2011;12(7):1817-1820.

125.  Kaya AO, Büyükberber S, Ozkan M, Alkiş N, Sevinc A, Ozdemir NY, Alici S,Esbah O, Berk V, Camci C, Ulas A, Coskun U, Benekli M; Anatolian Society ofMedical Oncology (ASMO). Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma. Asian Pacific Journal of Cancer Prevention 2012;13(2):463-467.

126.  Akyurek N, Uner A, Benekli M, Barista I. Prognostic significance of MYC,BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plusrituximab. Cancer 2012;118(17):4173-4183.

127.  Demirci U, Buyukberber S, Yılmaz G, Kerem M, Coskun U, Uner A, Baykara M,Pasaoglu H, Benekli M. Hepatotoxicity associated with lapatinib in an experimental rat model. European Journal of Cancer 2012;48(2):279-285.

128.  Demirci U, Buyukberber S, Coskun U, Benekli M. Isolated splenic metastasis and the role of positron emission tomography/ computerized tomography (PET/CT) in recurrent ovarian cancer. Türkiye Klinikleri Journal of Medical Sciences 2012;32:1721-1723.

129.  Tonyali O, Tufan G, Benekli M, Coskun U, Buyukberber S. Synchronous bilateral breast cancer in a patient with kindler syndrome. Clinical Breast Cancer 2012;12:145-146.

130.  Cetin B, Buyukberber S, Senturk S, Uluoglu O, Coskun U, Benekli M. A previously unreported malignancy of the thyroid. Medical Oncology 2012;29(3):1418-1420.

131.  Baykara M, Ozturk SC, Buyukberber S, Helvaci K, Ozdemir N, Alkis N, Berk V, Koca D, Coskun U, Oksuzoglu B, Uncu D, Arpaci E, Ustaalioglu BO, Demirci U, Kucukoner M, Dogu GG, Alici S, Akman T, Ozkan M, Aslan UY, Durnali AG, Benekli M. Clinicopathological features in bilateral breast cancer. Asian Pacific Journal of Cancer Prevention 2012;13(9):4571-4575.

132.  Demirci U, Buyukberber S, Yetisyigit T, Dizdar O, Benekli M, Alkis N, Coskun U; Anatolian Society of Medical Oncology (ASMO). Trabectedin in advanced soft tissue sarcoma: case series. Journal of BUON 2012;17(3):591-592.

133.  Yildiz R, Benekli M, Ozkan M, Alkis N, Berk V, Kaplan MA, Ciltas A, Karaca H, Durnali AG, Coskun U, Dikilitas M, Sevinc A, Dane F, Yetisyigit T, Dogu GG, Buyukberber S. Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. Journal of Cancer Research and Clinical Oncology 2012;138(11):1845-1852.

134.  Berk V, Ozdemir N, Ozkan M, Aksoy S, Turan N, Inal A, Balakan O, Yasar N, Unal OU, Benekli M, Durnali A, Colak D, Sonmez OU. XELOX versus FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 2012 Apr 25;59(120).

135.  Inal A, Kos FT, Algin E, Yildiz R, Berk V, Tugba Unek I, Colak D, Colak D, Kucukoner M, Tamer Elkiran E, Helvaci K, Geredeli C, Dane F, Balakan O, Ali Kaplan M, Gok Durnali A, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Gumus M, Ozkan M, Benekli M, Isikdogan A; Anatolian Society Of Medical Oncology. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study. Journal of BUON 2012;17(1):102-105.

136.  Demirci U, Ozdemir N, Benekli M, Babacan NA, Cetin B, Baykara M, Coskun U, Zengin N, Buyukberber S. Lymphoproliferative disorders in multiple primary cancers. Asian Pacific Journal of Cancer Prevention 2012;13(1):383-386.

137.  Kucukoner M, Isikdogan A, Arpaci E, Bilici M, Uncu D, Cetin B, Dane F, Inanc M, Kaplan MA, Cayir K, Yetisyigit T, Ozdemir N, Inal A, Aksoy S, Alkis N, Tekin SB, Eroglu C, Turhal S, Benekli M, Buyukberber S. Adjuvant chemoradiation for gastric cancer: Multicentric study of the Anatolian Society of Medical Oncology. Hepatogastroenterology 2012;59:2343-2347.

138.  Inal A, Kos FT, Algin E, Yildiz R, Dikiltas M, Unek IT, Colak D, Elkiran ET, Helvaci K, Geredeli C, Dane F, Balakan O, Kaplan MA, Durnali AG, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Gumus M, Kucukoner M, Ozkan M, Uncu D, Benekli M, Isikdogan A. Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study. Neoplasma 2012;59(3):297-301.

139.  Ozkan M, Berk V, Kaplan MA, Benekli M, Coskun U, Bilici A, Gumus M, Alkis N, Dane F, Ozdemir NY, Colak D, Dikilitas M. Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience. Neoplasma 2012;59(1):38-42.

140.  Seker M, Sevinc A, Yildiz R, Cihan S, Kaplan MA, Gokdurnali A, Dane F,Yaman E, Karaca H, Colak D, Uyeturk U, Bilici1 A, Ozdemir NY, Kalender ME, UncuD, Salepci1 T, Isikdogan A, Benekli M, Ozkan M, Gumus M, Coskun U, Camci C, Oksuzoglu B, Buyukberber S. Prognostic factors in gastrointestinal stromal tumors: Multicenter Experience of 333 Cases from Turkey. Hepatogastroenterology 2012 Nov 20;60(124).

141.  Kaya AO, Coskun U, Gumus M, Dane F, Ozkan M, Isıkdogan A, Alkis N, Buyukberber S, Yumuk F, Budakoglu B, Demirci U, Berk V, Bilici A, Inal A, Arpacı E, Benekli M; Anatolian Society of Medical Oncology (ASMO). The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. Journal of Chemotherapy 2012;24(4):217-220.

142.  Bozcuk H, Abali H, Coskun S; Lung Cancer Committee of Turkish Oncology Group.The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. World Journal of Surgical Oncology 2012;10(1):161.

143.  Demirci U, Buyukberber S, Coskun U, Akmansu M, Yaman E, Baykara M, Yamac D,Uner A, Benekli M. Long term experience in high grade glial tumors with temozolomide. Journal of BUON 2012 Apr-Jun;17(2):357-62.

144.  Turan N, Benekli M, Ozturk SC, Inal S, Memis L, Guz G, Cetin B, BuyukberberS. Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor. Annals of Pharmacotherapy 2012;46(10):e27.

145.  Demirci U, Yaman M, Buyukberber S, Coskun U, Baykara M, Uslu K, Ozet A, Benekli M, Bagriacik EU. Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy. International Immunopharmacology 2012;14(4):546-9. 

146.  Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Oksuzoglu B, Ozdemir NY,Yazilitas D, Benekli M, Uner A, Yamac D, Demirci U, Yildiz R, Karaca H, Unal OU, Bal O, Gumus M, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Nine-week trastuzumab treatment versus 52-week trastuzumab treatment forHER2-positive early-stage breast cancer. Journal of Cancer Research and Clinical Oncology 2012;138(12):2145-2151.

147.  Cetin B, Kaplan MA, Berk V, Ozturk SC, Benekli M, Isıkdogan A, Ozkan M,Coskun U, Buyukberber S. Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents. Asian Pacific Journal of Cancer Prevention 2012;13(3):1059-63.

148.  Babacan NA, Aksoy S, Cetin B, Ozdemir NY, Benekli M, Uyeturk U, Kaplan MA, Kos T, Karaca H, Oksuzoglu B, Zengin N, Buyukberber S. Multiple primary malignant neoplasms: Multi-center results from Turkey. Journal of BUON 2012; 17: 770-775.

149.  Kaya AO, Gunel N, Benekli M, Akyurek N, Buyukberber, Tatli H, Coskun, Yildiz, Yaman E, Ozturk B. Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients. Journal of BUON 2012; 17: 663-668.

150.  Baykara M, Coskun U, Berk V, Ozkan M, Kaplan MA, Benekli M, Karaca H, Inanc M, Isikdogan A, Sevinc A, Elkiran ET, Demirci U, Buyukberber S. Gemcitabine plus paclitaxel as second-line chemotherapy in patients with advanced non-small cell lung cancer. Asian Pacific Journal of Cancer Prevention 2012;13(10):5119-5124.

151.  Cetin B, Benekli M, Oksuzoglu B, Koral L, Ulas A, Dane F, Turker I, KaplanMA, Koca D, Boruban C, Yilmaz B, Sevinc A, Berk V, Isıkdogan A, Uncu D, Harputluoglu H, Coskun U, Buyukberber S. Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience. Onkologie 2012;35(12):740-5.

152.  Baykara M, Buyukberber S, Ozturk B, Coskun U, Unsal DK, Demirci U, Dane F,Kaplan MA, Bora H, Benekli M. Efficacy and safety of concomitant chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced squamous cell head and neck cancers. Asian Pacific Journal of Cancer Prevention 2013;14(4):2557-2561.

153.  Baykara M, Benekli M, Erdem O, Taskiran C, Demirci U, Vargol E, Gunaydin Y,Coskun U, Ozet A, Buyukberber S. Clear cell adenocarcinoma of the uterine cervix:A case report and review of the literature. Journal of Pediatric Hematology Oncology 2014;36:e131-3.

154.  Karaca H, Geredeli C, Kaplan MA, Demirci U, Alici S, Artac M, Isikdogan A, Benekli M, Balakan O, Arpaci E, Budakoglu B, Uncu D, Guler T, Berk V, Ozkan M. Efficacy and safety of erlotinib in previously treated advanced non-small cell lung cancer. UHOD 2013;23:1-6.

155.  Demirci U, Buyukberber S, Ozdemir N, Coskun U, Karaca H, Akmansu M, Yaman E, Baykara M, Yamac D, Uner A, Benekli M. Cyclophosphamide and carboplatin combination in recurrent malignant gliomas. UHOD 2013;3:178-183

156.  Alici S, Buyukberber S, Alkis N, Benekli M, Ozkan M, Bilici A, Demirci U,Karaca H, Arpaci E, Gumus M, Altunbas M, Dane F, Turk HM; Anatolian Society ofMedical Oncology. Low-dose docetaxel/cisplatin-leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma. Asian Pacific Journal of Cancer Prevention 2013;14(1):423-7.

157.  Tonyali O, Benekli M, Berk V, Coskun U, Ozkan M, Yildiz R, Ucgul E, Sevinc A,Uncu D, Demirci U, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Efficacy and toxicity of trastuzumab and paclitaxel plus capecitabine in the first-line treatment of HER2-positive metastatic breast cancer. Journal of Cancer Research and Clinical Oncology 2013;139(6):981-6.

158.  Demirci U, Tufan G, Aktas B, Balakan O, Alacacioglu A, Dane F, Engin H, KaplanMA, Gunaydin Y, Ozdemir NY, Tugba Unek I, Karaca H, Akman T, Sonmez OU, Coskun U,Harputluoglu H, Sevinc A, Tonyali O, Buyukberber S, Benekli M. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). Journal of Cancer Research and Clinical Oncology 2013;139(5):829-35.

159.  Uncu D, Aksoy S, Çetin B, Yetişyiğit T, Özdemir N, Berk V, Dane F, Inal A,Harputluoğlu H, Budakoğlu B, Koca D, Sevinç A, Cihan S, Durnalı AG, Özkan M, Öztürk MA, Işıkdoğan A, Büyükberber S, Benekli M, Köş T, Alkış N, Karaca H,Turhal NS, Zengin N; Anatolian Society of Medical Oncology. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysisof 667 patients. Oncology 2013;84(4):240-5.

160.  Cetin B, Atasever T, Akdemir UO, Senturk S, Tufan G, Turan N, Buyukberber S,Coskun U, Benekli M. The role of positron emission tomography with 18F-fluorodeoxyglucose in nodal staging of clinical and radiological N0 head and neck cancers. European Archives of Otorhinolaryngology 2013;270(8):2307-13.

161.  Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y,Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013 Jan 26;381(9863):303-12.

162.  Cetin B, Kaplan MA, Berk V, Tufan G, Benekli M, Isikdogan A, Ozkan M, Coskun U, Buyukberber S. Bevacizumab-containing chemotherapy is safe in patients withunresectable metastatic colorectal cancer and a synchronous asymptomatic primarytumor. Japanese Journal of Clinical Oncology 2013;43(1):28-32.

163.  Cetin B, Berk V, Kaplan MA, Afsar B, Tufan G, Ozkan M, Isikdogan A, Benekli M, Coskun U, Buyukberber S. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with metastatic renal cell carcinoma? Clinical Genitourinary Cancer 2013;11(2):141-148.

164.  Turan N, Benekli M, Koca D, Ustaalioglu BO, Dane F, Ozdemir N, Ulas A, Oztop I, Gumus M, Ozturk MA, Berk V, Kucukoner M, Uner A, Balakan O, Helvaci K, Ozkan S, Yilmaz U, Buyukberber S; Anatolian Society of Medical Oncology. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer. Oncology 2013;84(1):14-21.

165.  Cetin B, Benekli M, Dane F, Boruban C, Gumus M, Oksuzoglu B, Kaplan MA, Tufan G, Sevinc A, Coskun U, Buyukberber S. Lapatinib plus capecitabine for HER2-positive advanced-stage breast cancer in elderly women: Review of the Anatolian Society of Medical Oncology (ASMO) experience. Breast Care (Basel) 2013;8(1):67-70.

166.  Cetin B, Benekli M, Akyurek N, Senturk S, Koklu H, Karakus E, Coskun U,Buyukberber S. Isolated primary lymphomatoid granulomatosis of central nervous system. Indian Journal of Hematology and Blood Transfusion 2013;29(1):39-42.

167.  Oven Ustaalioglu BB, Unal OU, Turan N, Bilici A, Kaya S, Eren T, Ulas A, Inal A, Berk V, Demirci U, Alici S, Bal O, Benekli M, Gumus M. Prognostic factors for lymph node negative stage I and IIA non-small cell lung cancer: multicenter experiences. Asian Pacific Journal of Cancer Prevention 2013;14(11):6287-6292.

168.  Baykara M, Yaman M, Buyukberber S, Tufan G, Demirci U, Benekli M, Coskun U,Ozet A, Umit Bagriacik E. Clinical and prognostic importance of XIAP and USP8 in advanced stages of non-small cell lung cancer. Journal of BUON 2013;18(4):921-927.

169.  Baykara M, Buyukberber S, Ozturk B, Coskun U, Kaplan MA, Unsal DK, Dane F,Demirci U, Bora H, Benekli M. Anatolian Society of Medical Oncology. Efficacy and safety of concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced nasopharyngeal cancers. Tumori 2013;99(4):469-73.

170.  Cetin B, Afsar B, Deger SM, Gonul II, Gumusay O, Ozet A, Benekli M, Coskun U, Buyukberber S. Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma. International Urology and Nephrology 2014;46(6):1081-7.

171.  Kefeli U, Benekli M, Sevinc A, Yildiz R, Kaplan MA, Ciltas A, Balakan O,Isikdogan A, Coskun U, Dane F, Harputluoglu H, Karaca H, Yazilitas D, Durnali A, Kaya AO, Demirci U, Gumus M, Buyukberber S. Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience. Oncology Letters 2013;6(2):605-611.

172.  Tonyali O, Coskun U, Sener N, Inanc M, Akman T, Ulas A, Yazilitas D, Bal O,Kucukoner M, Yildirim Ozdemir N, Demirci U, Gunaydin Y, Yildiz R, Karaca H, Umit Unal O, Gumus M, Benekli M, Buyukberber S. Prognostic factors for recurrence-free survival in patients with HER2-positive early-stage breast cancer treated with adjuvant trastuzumab. Onkologie 2013;36(10):554-8.

173.  Saip P, Eralp Y, Sen F, Karaca H, Ozkan M, Cetin B, Benekli M, Kucukoner M, Isikdogan A, Un O, Basaran G, Onur H. Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breastcancer: a multicentric Turkish Oncology Group (TOG) trial. Breast 2013;22(5):628-633.

174.  Kefeli U, Buyukberber S, Akyol M, Yildiz R, Kaplan MA, Ciltas A, Sevinc A,Karaca H, Seker M, Ozdemir N, Alacacioglu A, Coskun U, Isikdogan A, Dane F, GumusM, Ozkan M, Suner A, Tarhan MO, Benekli M. Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience. Hepatogastroenterology 2013;60:647-652.

175.  Bozkurt O, Karaca H, Ciltas A, Kaplan MA, Benekli M, Sevinc A, Demirci U, Eren T, Kodaz H, Isikdogan A, Ozkan M, Buyukberber S. Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO). Asian Pacific Journal of Cancer Prevention 2014;15(4):1845-1849.

176.  Demirci U, Coskun U, Karaca H, Dane F, Ozdemir NY, Ulas A, Baykara M, Benekli M, Ozkan M, Buyukberber S. Docetaxel and cisplatin in first line treatment of patients with unknown primary cancer: a multicenter study of the Anatolian Society of Medical Oncology. Asian Pacific Journal of Cancer Prevention 2014;15(4):1581-1584.

177.  Turan N, Benekli M, Dane F, Unal OU, Kara HV, Koca D, Balvan O, Eren T, Tastekin D, Helvaci K, Berk V, Demirci U, Ozturk SC, Dogan E, etin B, Kucukoner M, Tonyali O, Tufan G, Oztop I, Gumus M, Coskun U, Uner A, Ozet A, Buyukberber S and for the Anatolian Society of Medical Oncology (ASMO). Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. Thoracic Cancer 2014;5:398-404.

178.  Aygencel G, Turkoglu M, Turkoz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. Journal of Critical Care 2014;29(4):618-26.

179.  Cetin B, Benekli M, Turker I, Koral L, Ulas A, Dane F, Oksuzoglu B, KaplanMA, Koca D, Boruban C, Yilmaz B, Sevinc A, Berk V, Uncu D, Harputluoglu H, Coskun U, Buyukberber S. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. Journal of Chemotherapy 2014;26:300-305.

180.  Baykara M, Kurt G, Buyukberber S, Demirci U, Ceviker N, Algin E, Coskun U,Aykol S, Emmez H, Ozet A, Benekli M. Management of brain metastases from non-small cell lung cancer. Journal of Cancer Research and Therapy 2014;10(4):915-921.

181.  Gumusay O, Cetin B, Ozet A, Demirci U, Buyukberber S, Coskun U, Algin E, Uner A, Yildiz R, Kurt G, Benekli M. Factors predicting recurrence in patients with grade III glial tumors: impact of adjuvant temozolomide on recurrence. Journal of BUON 2014;19(4):1035-1040.

182.  Algin E, Ozet A, Gumusay O, Cetin B, Akdemir UO, Benekli M, Coskun U, Uner A, Kapucu O, Buyukberber S. Association between survival and maximum standardized uptake value of liver metastases detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in patients with adenocarcinoma of unknown primary origin. Annals of Nuclear Medicine 2014;28(9):891-896.

183.  Mehmet K, Sener C, Uyeturk U, Seker M, Tastekin D, Tonyali O, Balakan O, Yazici OK, Urakci Z, Isikdogan A, Ozdemir N, Inal A, Kaplan MA, Suner A, Dal S, Uncu D, Gumus M, Boruban MC, Oksuzoglu B, Ayyildiz O, Benekli M. Treatment modalities in primary gastric lymphoma: the effect of rituximab and surgical treatment. A study by the Anatolian Society of Medical Oncology. Contemporary Oncology (Pozn) 2014; 18(4):273-278.

184.  Gumusay O, Ozet A, Baykara M, Cetin B, Coskun U, Buyukberber S, Uner A, Yildiz R, Benekli M. Second primary tumors in patients with head and neck cancer: A retrospective study from single center. Türkiye Klinikleri Journal of Medical Sciences 2014;34:262-266.

185.  Sendur MA, Ozdemir N, Özatlı T, Yazıcı O, Aksoy S, Ekinci AS, Yazılıtaş D, Günaydın Y, Oksuzoglu B, Benekli M, Zengin N. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen. Medical Oncology 2014;31(9):153.

186.  Yildiz BK, Ozdek S, Demirci U, Ceylanoglu KS, Ozmen MC, Baykara M, Buyukberber S, Coskun U, Benekli M. Functional and morphological effects of systemic bevacizumab on cancer patients' eyes. Optometry and Vision Science 2015;92(1):102-106.

187.  Benekli M, Yalcin S, Ozkan M, Elkiran ET, Sevinc A, Cabuk D, Coskun HS,Oksuzoglu B, Bayar B, Akbulat A, Ozet A. Efficacy of sorafenib in advanced differentiated and medullary thyroid cancer: experience in a Turkish population. Onco Targets Therapy 2015;8:1-5.

188.  Gumusay O, Yilmaz G, Aydil U, Ozet A, Tufan G, Erdem O, Kizil Y, Benekli M. Small cell neuroendocrine carcinoma of the posterior tongue. Journal of Cancer Research and Therapy 2015;11:651.

189.  Gumusay O, Benekli M, Ekinci O, Baykara M, Ozet A, Coskun U, Demirci U, Uner A, Dursun A, Atak EY, Buyukberber S. Discordances in Her2 status between primary gastric cancer and corresponding metastatic sites. Japanese Journal of Clinical Oncology 2015;45:416-421.

190.  Algin E, Ozet A, Gumusay O, Yilmaz G, Buyukberber S, Coskun U, Baykara M, Cetin B, Yıldız R, Benekli M. Liver metastases from adenocarcinomas of unknown primary site: management and prognosis in 68 consecutive patients. Wien Klin Wochenschr. 2016;128 (1-2): 42-47.

191.  Turan N, Benekli M, Unal OU, Unek İT, Tastekin D, Dane F, Algın E, Ulger S, Eren T, Topcu TO, Turkmen E, Babacan NA, Tufan G, Urakci Z, Ustaalioglu BO, Uysal OS, Ercelep OB, Taskoylu BY, Aksoy A, Canhoroz M, Demirci U, Dogan E, Berk V, Balakan O, Ekinci AŞ, Uysal M, Petekkaya İ, Ozturk SC, Tonyalı Ö, Çetin B, Aldemir MN, Helvacı K, Ozdemir N, Oztop İ, Coskun U, Uner A, Ozet A, Buyukberber  S; Anatolian Society of Medical Oncology (ASMO). Impact of adjuvant treatment modalities on survival outcomes in curatively resected pancreatic and periampullary adenocarcinoma. Chinese Journal of Cancer Research 2015;27(4):408-416.

192.  Unal OU, Oztop I, Menekse S, Urakci Z, Bozkurt O, Ozcelik M, Gunaydin Y, Yasar N, Yazilitas D, Kodaz H, Taskoylu BY, Aksoy A, Demirci U, Araz M, Tonyali O, Sevinc A, Yilmaz AU, Benekli M. Adult urological soft tissue sarcomas. Asian Pacific Journal of Cancer Prevention 2015;16(11):4777-4780.

193.  Baykara M, Benekli M, Ekinci O, Irkkan SC, Karaca H, Demirci U, Akinci MB, Unal OU, Dane F, Turkoz FP, Balakan O, Eser EP, Ozturk SC, Ozkan M, Oksuzoglu B,  Sevinc A, Demir N, Harputluoglu H, Yalcin B, Coskun U, Uner A, Ozet A, Buyukberber S; Anatolian Society of Medical Oncology (ASMO). Clinical significance of HER2 overexpression in gastric and gastroesophageal junction cancers. Journal of Gastrointestestinal Surgery 2015;19(9):1565-1571.

194.  Gumusay O, Ozet A, Buyukberber S, Baykara M, Coskun U, Cetin B, Uner A, Aydil U, Benekli M. Factors predicting the development of distant metastases in patients with head and neck squamous cell carcinoma: A retrospective study from a single centre. Journal of BUON 2015 Mar-Apr;20(2):521-526.

195.  Gumusay O, Cetin B, Benekli M, Gurcan G, Ilhan MN, Bostankolu B, Ozet A, Uner A, Coskun U, Buyukberber S. Factors influencing chemotherapy goal perception in newly diagnosed cancer patients. Journal of Cancer Education 2016;31:308-313.

196.  Cetin B, Gonul II, Buyukberber S, Afsar B, Gumusay O, Algın E, Turan N, Ozet A, Benekli M, Coskun U. The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors. Tumour Biology 2015;36(11):8471-8478.

197.  Tonyali O, Coskun U, Yuksel S, Inanc M, Bal O, Akman T, Yazilitas D, Ulas A, Kucukoner M, Aksoy A, Demirci U, Uysal M, Tanriverdi O, Gunaydin Y, Sumbul AT,Yildiz R, Karaca H, Oksuzoglu B, Ciltas A, Buyukberber S, Benekli M. Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab. Breast 2016 Feb;25:22-26.

198.  Aytekin A, Ciltas A, Sahinli H, Benekli M. The role of tyrosine kinase inhibitors in the treatment of renal cell carcinoma with brain metastases. Journal of BUON 2016 Jan-Feb;21(1):281-282.

199.  Gumusay O, Esendagli-Yilmaz G, Uner A, Cetin B, Buyukberber S, Benekli M, Ilhan MN, Coskun U, Gulbahar O, Ozet A. Crizotinib-induced toxicity in an experimental rat model. Wien Klin Wochenschr 2016 Jun;128(11-12):435-441.

200.  Esbah O, Demirci U, Dane F, Gunaydin Y, Ozdemir N, Siyar Ekinci A, Kodaz H, Yazilitas D, Rzayev R, Guney Y, Seker M, Uysal M, Inal A, Bilici A, Benekli M, Oksuzoglu B, Buyukberber S. Multicenter experience of adult medulloblastoma. Journal of BUON 2016;21(2):456-460.

201.  Erman M, Benekli M, Basaran M, Bavbek S, Buyukberber S, Coskun U, Demir G, Karabulut B, Oksuzoglu B, Ozkan M, Sevinc A, Yalcin S. Renal cell cancer: overview of the current therapeutic landscape. Expert Review of Anticancer Therapy 2016;19(9):1565-1571.